Amgen reported preliminary Phase 3 results for dazodalibep (a CD40 ligand antagonist) in Sjögren’s disease, saying the program met statistically significant and clinically meaningful goals. The fusion protein approach is positioned to compete against existing antibody-based strategies, with Amgen highlighting the trial outcome as a key inflection point ahead of regulatory discussions. The readout signals continued appetite for improved immunomodulation in a disease area that has remained underserved in approved therapies, and it comes as investors weigh how late-stage autoimmune assets can translate into differentiated mechanisms and durable clinical outcomes.